{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:47:15Z","timestamp":1783745235619,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate longitudinal change in hard exudate (HEs) volume over 5-years following anti-VEGF treatment for diabetic macular oedema (DMO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was a post-hoc analysis of structural optical coherence tomography (OCT) volume scans collected in the Diabetic Retinopathy Clinical Research Network Protocol T extension trial. A deep learning model was used to segment HEs and compute a HEs volume (mm\u00b3) for the entire OCT scan at baseline, 12, 24, 52, 104, 260 weeks (w). HEs volume was also quantified within the central subfield (CSF), inner ring (IR), and outer ring (OR) of ETDRS grid. Change in HEs over time was compared among treatment arms and a multiple regression analysis was used to evaluate the impact of HEs on visual outcomes relative to other biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      116 eyes were included (aflibercept: 44, bevacizumab: 30, ranibizumab: 42) in the final analysis. Across all studied regions, HEs significantly decreased through w52 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and from w52 to w104, a further significant decrease was observed in the total macula and IR, though no additional reduction between w104 and w260. Change in VA at w260 was associated with baseline VA and w260 change in CST, but not with baseline HEs. At w52, HEs reduction was significantly greater with aflibercept and ranibizumab compared to bevacizumab, but no longer significant at w104 and w260.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following anti-VEGF therapy, HEs decreased through w104, but stabilised after that, and initial differences among agents disappeared by two years. The change in HEs did not predict w260 visual outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04408-1","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:10:34Z","timestamp":1774692634000},"page":"1364-1370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema"],"prefix":"10.1038","volume":"40","author":[{"given":"Kangyeun","family":"Pak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changki","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"Srinivas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"4408_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ajo.2005.08.063","volume":"141","author":"TY Wong","year":"2006","unstructured":"Wong TY, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141:446\u2013455. e1.","journal-title":"Am J Ophthalmol"},{"key":"4408_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diab Care. 2012;35:556\u201364.","journal-title":"Diab Care"},{"key":"4408_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMra1005073","volume":"366","author":"DA Antonetti","year":"2012","unstructured":"Antonetti DA, Klein R, Gardner TW. Mechanisms of disease diabetic retinopathy. N Engl J Med. 2012;366:1227\u201339.","journal-title":"N Engl J Med"},{"key":"4408_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archopht.1996.01100140281004","volume":"114","author":"EY Chew","year":"1996","unstructured":"Chew EY, Klein ML, Ferris FL, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114:1079\u201384.","journal-title":"Arch Ophthalmol"},{"key":"4408_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615\u201325.","journal-title":"Ophthalmology"},{"key":"4408_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","volume":"122","author":"T Ishibashi","year":"2015","unstructured":"Ishibashi T, Li X, Koh A, Lai TY, Lee FL, Lee WK, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology. 2015;122:1402\u201315.","journal-title":"Ophthalmology"},{"key":"4408_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ajo.2015.12.025","volume":"164","author":"SB Bressler","year":"2016","unstructured":"Bressler SB, Glassman AR, Almukhtar T, Bressler NM, Ferris FL, Googe JM Jr, et al. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema. Am J Ophthalmol. 2016;164:57\u201368.","journal-title":"Am J Ophthalmol"},{"key":"4408_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep39161","volume":"6","author":"Y Mori","year":"2016","unstructured":"Mori Y, Suzuma K, Uji A, Ishihara K, Yoshitake S, Fujimoto M, et al. Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema. Sci Rep. 2016;6:39161.","journal-title":"Sci Rep"},{"key":"4408_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ajo.2019.11.014","volume":"211","author":"S Srinivas","year":"2020","unstructured":"Srinivas S, Verma A, Nittala MG, Alagorie AR, Nassisi M, Gasperini J, et al. Effect of intravitreal ranibizumab on intraretinal hard exudates in eyes with diabetic macular edema. Am J Ophthalmol. 2020;211:183\u201390.","journal-title":"Am J Ophthalmol"},{"key":"4408_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-017-0578-0","volume":"17","author":"YU Shin","year":"2017","unstructured":"Shin YU, Hong EH, Lim HW, Kang MH, Seong M, Cho H. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections. BMC Ophthalmol. 2017;17:1\u20139.","journal-title":"BMC Ophthalmol"},{"key":"4408_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3928\/23258160-20160324-02","volume":"47","author":"Y Kim","year":"2016","unstructured":"Kim Y, Yu S-Y, Kwak HW. En face spectral-domain optical coherence tomography imaging of outer retinal hard exudates in diabetic macular edema based on optical coherence tomography patterns. Ophthalmic Surg, Lasers Imaging Retin. 2016;47:313\u201321.","journal-title":"Ophthalmic Surg, Lasers Imaging Retin"},{"key":"4408_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ophtha.2014.10.028","volume":"122","author":"A Domalpally","year":"2015","unstructured":"Domalpally A, Ip MS, Ehrlich JS. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology. 2015;122:779\u201386.","journal-title":"Ophthalmology"},{"key":"4408_CR13","doi-asserted-by":"crossref","unstructured":"Pak K, Yoon C, Sadda SR. Comparative efficacy of aflibercept, bevacizumab, and ranibizumab on hard exudate resolution in diabetic macular edema. Canad J Ophthalmol. 2025;61:151\u20139.","DOI":"10.1016\/j.jcjo.2025.07.009"},{"key":"4408_CR14","doi-asserted-by":"crossref","unstructured":"Pak K, Yoon C, Sadda SR. Hard exudates in diabetic macular edema after intravitreal anti-VEGF therapy: a post-hoc analysis of the DRCR protocol T trial. Graefe\u2019s Arch Clin Exper Ophthalmol. 2025:264:427\u201336.","DOI":"10.1007\/s00417-025-07015-0"},{"key":"4408_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","volume":"127","author":"AR Glassman","year":"2020","unstructured":"Glassman AR, Wells JA III, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology. 2020;127:1201\u201310.","journal-title":"Ophthalmology"},{"key":"4408_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351\u20139.","journal-title":"Ophthalmology"},{"key":"4408_CR17","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1097\/IAE.0000000000003594","volume":"42","author":"G Mylonas","year":"2022","unstructured":"Mylonas G, Najeeb BH, Goldbach F, Deak GG, Michl M, Brugger J, et al. The impact of the vitreomacular interface on functional and anatomical outcomes in diabetic macular edema treated with three different anti-VEGF agents: post hoc analysis of the Protocol T study. Retina. 2022;42:2066\u201374.","journal-title":"Retina"},{"key":"4408_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1097\/IAE.0000000000002633","volume":"40","author":"NM Bressler","year":"2020","unstructured":"Bressler NM, Beaulieu WT, Bressler SB, Glassman AR, Melia BM, Jampol LM, et al. Anti\u2013vascular endothelial growth factor therapy and risk of traction retinal detachment in eyes with proliferative diabetic retinopathy: pooled analysis of five DRCR retina network randomized clinical trials. Retina. 2020;40:1021\u20138.","journal-title":"Retina"},{"key":"4408_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00715-z","volume":"11","author":"CK Yoon","year":"2025","unstructured":"Yoon CK, Lee HW, Kim HW, Kim JL. Deep learning based retinal hard exudates quantification of optical coherence tomography. Int J Retin Vitreous. 2025;11:114.","journal-title":"Int J Retin Vitreous"},{"key":"4408_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/096228029900800102","volume":"8","author":"JL Schafer","year":"1999","unstructured":"Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8:3\u201315.","journal-title":"Stat Methods Med Res"},{"key":"4408_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/bjophthalmol-2015-307797","volume":"100","author":"H Mehta","year":"2016","unstructured":"Mehta H, Fraser-Bell S, Yeung A, Campain A, Lim LL, Quin GJ, et al. Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial. Br J Ophthalmol. 2016;100:1000\u20134.","journal-title":"Br J Ophthalmol"},{"key":"4408_CR22","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1097\/IAE.0000000000000207","volume":"34","author":"SK Gelman","year":"2014","unstructured":"Gelman SK, Freund KB, Shah VP, Sarraf D. The pearl necklace sign: a novel spectral domain optical coherence tomography finding in exudative macular disease. Retina. 2014;34:2088\u201395.","journal-title":"Retina"},{"key":"4408_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","volume":"130","author":"SB Bressler","year":"2012","unstructured":"Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130:1153\u201361.","journal-title":"Arch Ophthalmol"},{"key":"4408_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/IAE.0000000000001545","volume":"38","author":"S Srinivas","year":"2018","unstructured":"Srinivas S, Nittala MG, Hariri A, Pfau M, Gasperini J, Ip M, et al. Quantification of intraretinal hard exudates in eyes with diabetic retinopathy by optical coherence tomography. Retina. 2018;38:231\u20136.","journal-title":"Retina"},{"key":"4408_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/tvst.9.2.21","volume":"9","author":"S Xie","year":"2020","unstructured":"Xie S, Okuwobi IP, Li M, Zhang Y, Yuan S, Chen Q. Fast and automated hyperreflective foci segmentation based on image enhancement and improved 3D U-Net in SD-OCT volumes with diabetic retinopathy. Transl Vis Sci Technol. 2020;9:21\u201321.","journal-title":"Transl Vis Sci Technol"},{"key":"4408_CR26","doi-asserted-by":"crossref","unstructured":"Yao C, Zhu W, Wang M, Zhu L, Huang H, Chen H, et al. SANet: a self-adaptive network for hyperreflective foci segmentation in retinal OCT images. SPIE; 2021;11596:809\u201315.","DOI":"10.1117\/12.2580699"},{"key":"4408_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2008.12.039","volume":"116","author":"M Bolz","year":"2009","unstructured":"Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914\u201320.","journal-title":"Ophthalmology"},{"key":"4408_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1167\/iovs.17-23042","volume":"59","author":"H Lee","year":"2018","unstructured":"Lee H, Jang H, Choi YA, Kim HC, Chung H. Association between soluble CD14 in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59:715\u201321.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4408_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajo.2016.02.002","volume":"164","author":"KC Chen","year":"2016","unstructured":"Chen KC, Jung JJ, Curcio CA, Balaratnasingam C, Gallego-Pinazo R, Dolz-Marco R, et al. Intraretinal hyperreflective foci in acquired vitelliform lesions of the macula: clinical and histologic study. Am J Ophthalmol. 2016;164:89\u201398.","journal-title":"Am J Ophthalmol"},{"key":"4408_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01733-0","volume":"7","author":"S Niu","year":"2017","unstructured":"Niu S, Yu C, Chen Q, Yuan S, Lin J, Fan W, et al. Multimodality analysis of hyper-reflective foci and hard exudates in patients with diabetic retinopathy. Sci Rep. 2017;7:1568.","journal-title":"Sci Rep"},{"key":"4408_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03529-8","volume":"7","author":"M Miura","year":"2017","unstructured":"Miura M, Makita S, Sugiyama S, Hong YJ, Yasuno Y, Elsner AE, et al. Evaluation of intraretinal migration of retinal pigment epithelial cells in age-related macular degeneration using polarimetric imaging. Sci Rep. 2017;7:3150.","journal-title":"Sci Rep"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04408-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04408-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:54:29Z","timestamp":1781510069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04408-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4408"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04408-1","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. SRS Consultant (C): 4DMT, Abbvie, Alexion, Allergan Inc., Alnylam Pharmaceuticals, Amgen Inc., Apellis Pharmaceuticals, Inc., Astellas, Bayer Healthcare Pharmaceuticals, Biogen MA Inc., Boehringer Ingelheim, Carl Zeiss Meditec, Catalyst Pharmaceuticals Inc., Centervue Inc., GENENTECH, Gyroscope Therapeutics, Heidelberg Engineering, Hoffman La Roche, Ltd., Iveric Bio, Janssen Pharmaceuticals Inc., Nanoscope, Notal Vision Inc., Novartis Pharma AG, Optos Inc., Oxurion\/Thrombogenics, Oyster Point Pharma, Regeneron Pharmaceuticals Inc., Samsung Bioepis, Topcon Medical Systems Inc. Recipient (R): Carl Zeiss Meditec, Heidelberg Engineering, Nidek Incorporated, Novartis Pharma AG, Topcon Medical Systems Inc. Financial Support (F): Carl Zeiss Meditec, Heidelberg Engineering, Optos Inc., Nidek, Topcon, Centervue.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}